Axsome Therapeutics Statistics
Total Valuation
LON:0HKF has a market cap or net worth of GBP 5.68 billion. The enterprise value is 5.60 billion.
| Market Cap | 5.68B |
| Enterprise Value | 5.60B |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 50.41M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.38% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 76.80% |
| Float | 42.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.61 |
| PB Ratio | 103.63 |
| P/TBV Ratio | 390.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -32.82 |
| EV / Sales | 13.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -74.31 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 2.96.
| Current Ratio | 1.57 |
| Quick Ratio | 1.45 |
| Debt / Equity | 2.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.16 |
| Interest Coverage | -25.65 |
Financial Efficiency
Return on equity (ROE) is -275.50% and return on invested capital (ROIC) is -42.17%.
| Return on Equity (ROE) | -275.50% |
| Return on Assets (ROA) | -19.79% |
| Return on Invested Capital (ROIC) | -42.17% |
| Return on Capital Employed (ROCE) | -63.06% |
| Revenue Per Employee | 511,699 |
| Profits Per Employee | -209,258 |
| Employee Count | 683 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 2.40 |
Taxes
| Income Tax | -650,948 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +79.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +79.43% |
| 50-Day Moving Average | 141.99 |
| 200-Day Moving Average | 119.10 |
| Relative Strength Index (RSI) | 65.34 |
| Average Volume (20 Days) | 274 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.58 |
Income Statement
In the last 12 months, LON:0HKF had revenue of GBP 417.55 million and -170.75 million in losses. Loss per share was -3.47.
| Revenue | 417.55M |
| Gross Profit | 383.58M |
| Operating Income | -144.95M |
| Pretax Income | -171.41M |
| Net Income | -170.75M |
| EBITDA | -139.82M |
| EBIT | -144.95M |
| Loss Per Share | -3.47 |
Balance Sheet
The company has 241.98 million in cash and 162.62 million in debt, giving a net cash position of 79.36 million.
| Cash & Cash Equivalents | 241.98M |
| Total Debt | 162.62M |
| Net Cash | 79.36M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 54.85M |
| Book Value Per Share | 1.09 |
| Working Capital | 152.55M |
Cash Flow
In the last 12 months, operating cash flow was -75.10 million and capital expenditures -326,590, giving a free cash flow of -75.43 million.
| Operating Cash Flow | -75.10M |
| Capital Expenditures | -326,590 |
| Free Cash Flow | -75.43M |
| FCF Per Share | n/a |
Margins
Gross margin is 91.86%, with operating and profit margins of -34.71% and -40.89%.
| Gross Margin | 91.86% |
| Operating Margin | -34.71% |
| Pretax Margin | -41.05% |
| Profit Margin | -40.89% |
| EBITDA Margin | -33.49% |
| EBIT Margin | -34.71% |
| FCF Margin | n/a |
Dividends & Yields
LON:0HKF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.38% |
| Shareholder Yield | -3.38% |
| Earnings Yield | -3.00% |
| FCF Yield | -1.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0HKF has an Altman Z-Score of 2.8 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 4 |